Bio Green Med Solution, Inc. (BGMS) AI Stock Analysis
BGMS AI stock analysis summary
AI ResearchBio Green Med Solution, Inc. (BGMS) is a Malaysia-based company engaged in protective and fire safety systems as well as pharmaceutical research and development. In FY2025, the company generated $747,000 in revenue, representing 1637.2% annual growth, while posting a net income of -$3.0M. Over the trailing twelve months ended June 30, 2026, revenue totaled $1.9M with a net profit margin of -118.3%.
- Market cap
- $6.0M
- Revenue (TTM)
- $1.9M
- P/E
- —
- 1Y return
- -76.1% S&P 500 16.8%
- Avg. target
- —
Bull case
- Trailing twelve-month quarterly revenue grew 710.0% year-over-year as of June 30, 2026.
- The company maintains liquidity with a current ratio of 8.63 and cash and short-term investments of $3.8M.
- Net losses narrowed significantly in FY2025 to -$3.0M from -$11.2M in FY2024 and -$22.6M in FY2023.
Bear case
- The stock has lost 76.1% over the past year and 100.0% over the trailing five-year period.
- The company's five-year revenue CAGR from FY2015 to FY2025 is -17.4%, alongside an operating margin of -124.4% for the trailing twelve months.
- Dilution has been severe, with the five-year share count change reaching 207259.3%.
What Bio Green Med Solution does
Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, as well as fire protection and prevention systems. The company is also involved in the research and development of pharmaceuticals. Founded in 1996 and headquartered in Kuala Lumpur, Malaysia, the company was formerly known as Cyclacel Pharmaceuticals, Inc. before changing its name to Bio Green Med Solution, Inc. in September 2022. It is listed on the NASDAQ exchange and operates in the building products and equipment industry within the industrials sector.
Growth and profitability
Bio Green Med Solution experienced significant revenue fluctuations over recent fiscal periods. In FY2023, revenue was $420,000 with a net income of -$22.6M. In FY2024, revenue fell 89.8% to $43,000, and net income was -$11.2M. For FY2025, revenue expanded 1637.2% to $747,000, while gross margin was 18.5% and net income was -$3.0M. From FY2015 to FY2025, revenue delivered a 5-year CAGR of -17.4%. For the trailing twelve months ended June 30, 2026, revenue reached $1.9M, accompanied by an operating margin of -124.4% and quarterly revenue growth of 710.0% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, Bio Green Med Solution reported cash and short-term investments of $3.8M, total assets of $7.9M, and shareholders' equity of $7.2M. The company held a current ratio of 8.63. For FY2025, operating cash flow and free cash flow both stood at -$4.8M, while research and development expenses were $848,000. In addition, the company paid $61,000 in dividends in FY2025, and its five-year share count change was 207259.3%.
Valuation and performance
Bio Green Med Solution trades at a price-to-sales multiple of 3.2x, which is above the 1.5x median of its US-listed Industrials peers. Its enterprise value to EBITDA ratio is 0.0x compared to the peer median of 13.9x, and its price-to-book ratio is 0.9x. The company's market cap stands at $6.0M with an enterprise value of $2.6M. Over the past year, the stock declined 76.1%, underperforming the S&P 500 (SPY) return of 16.8%. Over a five-year timeframe, the stock has declined 100.0% compared to an 83.0% gain for the benchmark index.
What analysts expect
Bio Green Med Solution does not have published analyst coverage, recommendations, or consensus price targets in the provided records. The company has beaten EPS expectations in 4 of its last 4 quarters. Bio Green Med Solution's next scheduled earnings date is November 12, 2026. Institutional ownership is 1.5%, while insider ownership accounts for 33.9%, and short interest represents 0.1% of float.
Key risks and what to watch
- Negative free cash flow of -$4.8M in FY2025 continues to deplete financial resources.
- A trailing twelve-month profit margin of -118.3% reflects ongoing operational unprofitability.
- The five-year share count increase of 207259.3% presents ongoing risk of shareholder dilution.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this BGMS AI stock analysis
This page is an AI-written research summary of Bio Green Med Solution, Inc. (BGMS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: BGMS income statement, BGMS balance sheet, BGMS key metrics, BGMS chart. See the BGMS stock overview for the latest quote and news.
BGMS AI stock analysis FAQ
What does Bio Green Med Solution, Inc. do?
Bio Green Med Solution, Inc. engages in the distribution, trading, and installation of fire safety materials and systems, and is also involved in pharmaceutical research and development.
When is BGMS's next earnings report?
The next scheduled earnings report date is November 12, 2026.
How has BGMS stock performed over the past year?
BGMS shares have declined 76.1% over the past 12 months as of October 16, 2026, while the S&P 500 returned 16.8%.
What was Bio Green Med Solution's revenue growth in FY2025?
In FY2025, revenue grew 1637.2% to $747,000, up from $43,000 in FY2024.